MedTrace Logo

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

NCT02820558 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-05-21

No results posted yet for this study

Summary

This study evaluates the delivery of substance P via the celiac artery in the treatment of recent onset type 1 diabetes.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Substance P

Sponsors & Collaborators

  • Vanilloid Genetics Inc.

    lead INDUSTRY

Principal Investigators

  • Etienne Sochett, MD · Hospital for Sick Children, Toronto Ontario

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02820558 on ClinicalTrials.gov